Japan Regenerative Medicine Laws Take Effect, Encourage Industry
This article was originally published in PharmAsia News
Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.
You may also be interested in...
Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.
Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.